Curbstone Financial Management Corp lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 162.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,686 shares of the medical equipment provider’s stock after acquiring an additional 2,903 shares during the quarter. Curbstone Financial Management Corp’s holdings in Zimmer Biomet Holdings were worth $549,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in ZBH. BlackRock Inc. grew its stake in shares of Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock worth $2,044,168,000 after acquiring an additional 16,336,262 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Zimmer Biomet Holdings by 92.7% in the second quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock worth $421,146,000 after acquiring an additional 1,577,874 shares during the period. Harbour Capital Advisors LLC grew its stake in shares of Zimmer Biomet Holdings by 13,131.3% in the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock worth $10,145,000 after acquiring an additional 1,292,773 shares during the period. Koch Industries Inc. grew its stake in shares of Zimmer Biomet Holdings by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock worth $1,033,000 after acquiring an additional 1,038,674 shares during the period. Finally, Glenview Capital Management LLC bought a new stake in shares of Zimmer Biomet Holdings in the first quarter worth approximately $94,197,000. Hedge funds and other institutional investors own 85.22% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded down 0.09% during trading on Thursday, reaching $120.58. 81,071 shares of the company’s stock traded hands. The company has a 50 day moving average price of $116.60 and a 200-day moving average price of $120.35. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.49. The stock has a market cap of $24.38 billion, a P/E ratio of 34.34 and a beta of 1.19.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by ($0.02). The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. Zimmer Biomet Holdings’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.02 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post $8.23 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. Zimmer Biomet Holdings’s payout ratio is 27.59%.

ZBH has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Morgan Stanley lifted their price target on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, July 17th. Oppenheimer Holdings, Inc. set a $137.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Monday, August 14th. BMO Capital Markets reiterated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $136.55.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-shares-bought-by-curbstone-financial-management-corp/1641310.html.

In related news, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.07% of the stock is currently owned by company insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.